Search PubMed⌕ Search

Biomedical subjects

F Ledda

Publications and source records attributed to F Ledda.

At least 127 records · Page 7Linked to original sources
PubMed1973

Effects of noradrenaline and isoprenaline, in combination with - and -receptor blocking substances, on the action potential of cardiac Purkinje fibres.

1. The effects of noradrenaline and isoprenaline on the repolarization phase of the action potential have been studied in the Purkinje fibres of sheep heart, electrically driven at constant rates.2. Isoprenaline (2, 5 and 8 x 10(-8) g/ml.) increases the slope of phase 2 of repolarization and decreases the plateau length; the resulting decrease in action potential duration is concentration dependent, but not rate dependent.3. The effect of isoprenaline on the action potential duration is entirely blocked by propranolol (10(-7) g/ml.) and unaffected by phentolamine (5 x 10(-7) g/ml.).4. In phentolamine (5 x 10(-7) g/ml.) pretreated preparations the response induced by noradrenaline (5 x 10(-8), 1 and 5 x 10(-7) g/ml.) is very similar to that induced by isoprenaline.5. In propranolol (2.5 x 10(-7) g/ml.) pretreated preparations noradrenaline causes a lengthening of the plateau phase and an increase in action potential duration.6. The relationship of these results to the presence of both alpha- and beta-receptors in cardiac Purkinje fibres is discussed.

Action Potentials↗
PubMedDate not supplied

Enhancement of the vasoconstrictor response to KCL by nitric oxide synthesis inhibition: a comparison with noradrenaline.

The role of the vascular endothelium in the response to a vasoconstrictor agent acting through a non-receptorial mechanism, such as KCl, was tested in the isolated mesenteric vascular bed of the rat. It was confirmed that the vasoconstrictor response evoked by stimulation of sympathetic terminals was unaffected by 100 microM NG-nitro-D-arginine methyl ester (D-NAME), but was significantly potentiated by 100 microM NG-nitro-L-arginine methyl ester (L-NAME) and by removal of endothelium. Responses to exogenous noradrenaline (1-100 microM) were also enhanced by treatment with 100 microM NG-monomethyl-L-arginine (L-NMMA) and with L-NAME, but not with D-NAME. The potentiating effect of NO synthesis inhibitors was reversed by 1 mM L-arginine. Moreover, the noradrenaline-induced vasoconstriction was significantly increased by endothelium-deprivation. Potassium chloride (80 mM) induced a vasoconstrictor response which was not modified by pretreatment with prazosin (0.1 microM) and yohimbine (0.1 microM). The response to KCl was unaffected by D-NAME (100 microM) but the L-stereoisomer induced a significant increase in the perfusion pressure. In endothelium-denuded preparations the vasoconstrictor response to KCl was greater than in control conditions and was quantitatively similar to that observed in L-NAME-treated preparations. The responses to electrical field stimulation, noradrenaline and KCl in endothelium-denuded preparations were not modified by L-NAME. The results suggest that an increase in vascular tone, per se, may represent a trigger for the release of endothelium-derived relaxing factor from endothelial cells.

Amino Acid Oxidoreductases↗
PubMedDate not supplied

Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells.

Initial studies have demonstrated the therapeutic efficacy for cancer treatment of in vivo transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir (GCV) treatment. However, recent studies have questioned the validity of this approach. Using retroviral vector-producing cells (VPC) as a source for in vivo gene transfer, we evaluated the efficacy of in vivo transduction of malignant cells using three different tumor cell models: B16 murine and IIB-MEL-LES human melanomas and a C6 rat glioblastoma. In vitro studies showed a bystander effect only in C6 cells. In vivo studies showed an inhibition of tumor growth in the two melanoma models when tumor cells were coinjected with VPC-producing retroviral vectors carrying the herpes simplex virus thymidine kinase gene, followed by GCV treatment; however, 100% of mice developed tumors in both models. Under similar experimental conditions, 70% (7 of 10) of syngeneic rats completely rejected stereotactically transferred C6 tumor cells; most of them (5 of 10) showed a prolonged survival. Treating established C6 tumors with VPC-producing retroviral vectors carrying the herpes simplex virus thymidine kinase gene and GCV led to the cure of 33% (4 of 12) of the animals. Rats that rejected tumor growth developed an antitumor immune memory, leading to a rejection of a stereotactic contralateral challenge with parental cells. The immune infiltrate, which showed the presence of T lymphocytes, macrophages, and polymorphonuclear cells at the site of the first injection and mainly T lymphocytes and macrophages at the site of tumor challenge, strengthened the importance of the immune system in achieving complete tumor rejection.

Animals↗
PubMedDate not supplied

Induction by histamine of oscillatory activity in sheep Purkinje fibers and suppression by verapamil or lidocaine.

Histamine (1--2 x 10(-5) M) induced or enhanced oscillatory activity in four of five sheep Purkinje fibers depolarized by a low-potassium medium. These effects of histamine were readily antagonized by 2 x 10(-5) M burimamide but were unaffected by 10(-5) M practolol. Oscillatory activity was consistently induced or enhanced by 5 x 10(-6) M adrenaline in five preparations. Oscillatory activity, whether induced by histamine or adrenaline, was always abolished by verapamil (0.22--2.2 x 10(-6 M) but in only one of five experiments by lidocaine (4.2 x 10(-5) M). We conclude that induction of oscillatory responses may be added to the other arrhythmogenic mechanisms produced by histamine through the stimulation of H2 receptors. We confirmed that oscillatory activity is very effectively suppressed by verapamil.

Action Potentials↗